Oasmia Pharmaceutical AB
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also offers Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixi… Read more
Oasmia Pharmaceutical AB - Asset Resilience Ratio
Oasmia Pharmaceutical AB (OASMY) has an Asset Resilience Ratio of 0.31% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Oasmia Pharmaceutical AB's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Oasmia Pharmaceutical AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $470.00K | 0.31% |
| Total Liquid Assets | $470.00K | 0.31% |
Asset Resilience Insights
- Limited Liquidity: Oasmia Pharmaceutical AB maintains only 0.31% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Oasmia Pharmaceutical AB Industry Peers by Asset Resilience Ratio
Compare Oasmia Pharmaceutical AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Oasmia Pharmaceutical AB (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Oasmia Pharmaceutical AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 18.23% | $31.51 Million | $172.88 Million | -14.74pp |
| 2023-12-31 | 32.97% | $72.75 Million | $220.67 Million | -4.42pp |
| 2022-12-31 | 37.39% | $133.05 Million | $355.88 Million | +22.35pp |
| 2021-12-31 | 15.04% | $89.36 Million | $594.31 Million | -13.60pp |
| 2020-12-31 | 28.64% | $247.28 Million | $863.54 Million | +5.35pp |
| 2019-12-31 | 23.28% | $234.08 Million | $1.01 Billion | +23.28pp |
| 2018-12-31 | 0.00% | $1.00 | $646.38 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $568.08 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $521.58 Million | -- |
| 2015-12-31 | 3.88% | $20.01 Million | $515.58 Million | -5.87pp |
| 2014-12-31 | 9.75% | $50.15 Million | $514.57 Million | -- |